NEW YORK, May 7 – Applied Biosystems and BioVision have agreed to jointly develop mass spectrometry tools for proteomics applications, the companies said Monday.
BioVision, based in Hannover, Germany, has worked since 1999 with ABI's German subsidiary to test and demonstrate how ABI tools can be applied to proteomics. The expanded collaboration will give BioVision input into the development of new ABI mass spectrometers and associated equipment.
Under the agreement, the two companies will build a European reference laboratory in Hannover, where BioVision scientists will investigate new techniques for studying proteins using ABI mass spectrometers. In addition, “people who are interested in ABI tools can see them working with new applications,” said a spokeswoman for BioVision.
The companies did not disclose the financial details of the collaboration.
"BioVision has developed some very creative approaches to protein and peptide purification and analysis," Jay Smith, director and product line manager for MALDI-TOF MS and biochromatography at Applied Biosystems, said in a statement. "We see them as a key partner in shaping and developing our next generation of high-throughput tools."Four year-old BioVision performs differential display analysis of human blood and other body fluids to identify disease markers and drug targets. The company has a research contract with Roche, and a collaboration with Matrix Science, a British developer of software for integrating mass spectrometry with other bioinformatics tools.